Encorafenib

468 interactions 398 cited references
Also sold as: Braftovi Braftovi®
About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide
36 Contraindicated 392 Major 40 Moderate
All (468) Contraindicated (36) Major (392) Moderate (40)

Major

Encorafenib Zongertinib Hernexeos Reduced zongertinib exposure and reduced efficacy of zongertinib Details Encorafenib Zotepine Increased risk of QT interval prolongation Details Encorafenib Zuclopenthixol Increased risk of QT interval prolongation Details Encorafenib Eribulin Injection Halaven Increased risk of QT interval prolongation Details Encorafenib Estradiol Topical Divigel Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Estradiol Transdermal Patch Alora® Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Famotidine Injection Calmicid Increased risk of QT interval prolongation Details Encorafenib Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Encorafenib Gatifloxacin Ophthalmic Zymar® Increased risk of QT interval prolongation Details Encorafenib Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Encorafenib Granisetron Transdermal Patch Sancuso Increased risk of QT interval prolongation Details Encorafenib Granisetron Injection Granisol Increased risk of QT interval prolongation Details Encorafenib Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Encorafenib Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Encorafenib Letermovir Injection Prevymis Increased encorafenib/letermovir exposure, an increased risk of encorafenib-related adverse events and an increased risk of leterm... Details Encorafenib Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Encorafenib Levonorgestrel Intrauterine System Kyleena Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Lurbinectedin Injection Zepzelca Reduced lurbinectedin exposure and reduced efficacy of lurbinectedin Details Encorafenib Medroxyprogesterone Injection Depo-Provera Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Metronidazole Injection Flagyl Increased risk of QT interval prolongation Details Encorafenib Metronidazole Topical MetroCream® Increased risk of QT interval prolongation Details Encorafenib Metronidazole Vaginal MetroGel® Vaginal Increased risk of QT interval prolongation Details Encorafenib Midazolam Nasal Spray Nayzilam Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Midazolam Injection Nayzilam Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Moxifloxacin Injection Avelox Increased risk of QT interval prolongation Details Encorafenib Moxifloxacin Ophthalmic Moxeza® Increased risk of QT interval prolongation Details Encorafenib Nafcillin Injection Unipen® Injection Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Octreotide Injection Bynfezia Increased risk of QT interval prolongation Details Encorafenib Ofloxacin Ophthalmic Ocuflox Increased risk of QT interval prolongation Details Encorafenib Ofloxacin Otic Floxin® Otic Increased risk of QT interval prolongation Details Encorafenib Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Encorafenib Oxaliplatin Injection Eloxatin® Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.